Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is a placebo-controlled blinded clinical evaluation of day and night skin care creams supplemented by Medicell Technology's composition of defensins and supportive molecules determine the skin hydration and anti-aging properties of the topical test articles after repeated application to the skin of human subjects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Advanced Dermatology
• Treatments: Defensins

Criteria

Inclusion Criteria:

• Sex: Female

• Fitzpatrick Skin Types: I-VI

• Age: 40 - 75 years

• Individuals who will be able to read, understand and give an informed consent relation to the study they are participating in.

• Individuals who will be free of any dermatological or systemic disorder, which in the Principal Investigator's opinion, could interfere with the study results.

• Individuals who will be in general good health and who will complete a preliminary medical history form mandated by the clinic.

• Individuals who will be able to and agree to cooperate with the Investigator and research staff.

• Individuals who will agree to have test products applied in accordance with the protocol and are able to complete the full course of the study.

• Individuals who will agree to have 2 biopsies on the postauricular area if randomly selected.

• Individuals who will agree to not participate in any other study during the entire length of the study and have not participated in a similar study in the past 30 days.

Exclusion Criteria:

• Individuals who are currently taking any medications (topical or systemic) that may mask or interfere with the test results.

• Individuals who have a history of any acute or chronic disease that might interfere with or increase the risk on study participation. (e.g., systemic lupus erythematosus, rheumatoid arthritis, HIV positive).

• Individuals who are diagnosed with chronic skin allergies (atopic dermatitis/eczema) or recently treated skin cancer within the last 12 months.

• Individuals who control their diabetes using insulin.

• Individuals with any history, which in the Investigator's opinion, indicates the potential for harm to the subject or places the validity of the study in jeopardy.

• Individuals who indicate that they are pregnant or are planning to become pregnant or nursing.

• Individuals who have undergone any of the following procedures:

• Botox within 6 months before enrollment into study and until study completion

• Injectable filler within 3 months before enrollment into study and until study completion

• Lasers or tissue tightening devices (ultherapy, radiofrequency, skin tightening, microcurrent or photorejuvenation, photodynamic therapy) within 6 months before enrollment into study and until study completion

• Sculptra or Bellafill prior to enrollment into the study and until study completion